How MRNA is Misspliced in Acute Myelogenous Leukemia (AML)?

Overview

Journal Oncotarget

Specialty Oncology

Date 2014 Nov 7

PMID 25375204

Citations 6

Authors

Aminetou Mint Mohamed

Morgan Thenoz

Francoise Solly

Marie Balsat

Franck Mortreux

Eric Wattel

Affiliations

Soon will be listed here.

Abstract

Approximately one-third of expressed genes are misspliced in AML, opening the possibility that additional factors than splicing factor mutations might cause RNA missplicing in these diseases. AML cells harbor a constellation of epigenetic modifications and regularly express large amounts of WT1 transcripts. Histone acetylation/methylation and DNA CpG methylation favor either exon skipping or inclusion, mainly through interfering with RNA Pol II-mediated elongation. This can result either from the binding of various factors on Pol II or alternatively from the recruitment of DNA binding factors that create roadblocks to Pol II-induced elongation. WT1 exhibits pleiotropic effects on mRNA splicing, which mainly result from the binding properties of WT1 via its zinc fingers domains to DNA, RNA, and proteins. Through the repression of the kinase SRPK1, WT1 modifies the splicing of VEGF, which plays important roles in hematopoiesis and angiogenesis. At the protein level, WT1 interacts with the splicing factors U2AF2, WTAP, and RPM4. Therefore, AML cells appear to have acquired numerous properties known to interfere with mRNA splicing. The challenge is now to elucidate these links in order to trigger mRNA splicing at the therapeutic level.

Citing Articles

Icariside Ⅱ Attenuates Palmitic Acid-Induced Endothelial Dysfunction Through SRPK1-Akt-eNOS Signaling Pathway.

Gu Y, Tan X, Song W, Song W, Yuan Y, Xin Z Front Pharmacol. 2022; 13:920601.

PMID: 35846993 PMC: 9280058. DOI: 10.3389/fphar.2022.920601.

Splicing machinery genomics events in acute myeloid leukaemia (AML): in search for therapeutic targets, diagnostic and prognostic biomarkers.

Dlamini Z, Shoba B, Hull R Am J Cancer Res. 2020; 10(9):2690-2704.

PMID: 33042611 PMC: 7539770.

Hypoxia-Inducible Factor1-Α (HIF1α) and Vascular Endothelial Growth Factor-A (VEGF-A) Expression in De Novo AML Patients.

Jabari M, Farsani M, Salari S, Hamidpour M, Amiri V, Mohammadi M Asian Pac J Cancer Prev. 2019; 20(3):705-710.

PMID: 30909668 PMC: 6825791. DOI: 10.31557/APJCP.2019.20.3.705.

[The aberrant epigenetic regulation and epigenomic landscape alteration in human acute myelogenous leukemia and the emerged agents that target epigenetic regulators].

Chen Z Zhonghua Xue Ye Xue Za Zhi. 2019; 40(1):78-82.

PMID: 30704236 PMC: 7351702. DOI: 10.3760/cma.j.issn.0253-2727.2019.01.017.

Aberrant splicing and drug resistance in AML.

de Necochea-Campion R, Shouse G, Zhou Q, Mirshahidi S, Chen C J Hematol Oncol. 2016; 9(1):85.

PMID: 27613060 PMC: 5018179. DOI: 10.1186/s13045-016-0315-9.

References

Kornblihtt A, Schor I, Allo M, Dujardin G, Petrillo E, Munoz M . Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol. 2013; 14(3):153-65. DOI: 10.1038/nrm3525. View

Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

Cebe Suarez S, Pieren M, Cariolato L, Arn S, Hoffmann U, Bogucki A . A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci. 2006; 63(17):2067-77. PMC: 11136335. DOI: 10.1007/s00018-006-6254-9. View

Morrison A, Venables J, Dellaire G, Ladomery M . The Wilms tumour suppressor protein WT1 (+KTS isoform) binds alpha-actinin 1 mRNA via its zinc-finger domain. Biochem Cell Biol. 2006; 84(5):789-98. DOI: 10.1139/o06-065. View

Visconte V, Makishima H, Maciejewski J, Tiu R . Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. Leukemia. 2012; 26(12):2447-54. PMC: 3645466. DOI: 10.1038/leu.2012.130. View

Anensen N, Hjelle S, Van Belle W, Haaland I, Silden E, Bourdon J . Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene. 2011; 31(12):1533-45. DOI: 10.1038/onc.2011.348. View

Blencowe B . Alternative splicing: new insights from global analyses. Cell. 2006; 126(1):37-47. DOI: 10.1016/j.cell.2006.06.023. View

Larsson S, Charlieu J, Miyagawa K, Engelkamp D, Rassoulzadegan M, Ross A . Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell. 1995; 81(3):391-401. DOI: 10.1016/0092-8674(95)90392-5. View

Nishida S, Hosen N, Shirakata T, Kanato K, Yanagihara M, Nakatsuka S . AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood. 2005; 107(8):3303-12. DOI: 10.1182/blood-2005-04-1656. View

10.

Amin E, Oltean S, Hua J, Gammons M, Hamdollah-Zadeh M, Welsh G . WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell. 2011; 20(6):768-80. PMC: 3574979. DOI: 10.1016/j.ccr.2011.10.016. View

11.

Ley T, Ding L, Walter M, McLellan M, Lamprecht T, Larson D . DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; 363(25):2424-33. PMC: 3201818. DOI: 10.1056/NEJMoa1005143. View

12.

Nowak D, Amin E, Rennel E, Hoareau-Aveilla C, Gammons M, Damodoran G . Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem. 2009; 285(8):5532-40. PMC: 2820781. DOI: 10.1074/jbc.M109.074930. View

13.

Morrison A, Viney R, Ladomery M . The post-transcriptional roles of WT1, a multifunctional zinc-finger protein. Biochim Biophys Acta. 2007; 1785(1):55-62. DOI: 10.1016/j.bbcan.2007.10.002. View

14.

Ochsenreither S, Fusi A, Busse A, Bauer S, Scheibenbogen C, Stather D . "Wilms Tumor Protein 1" (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow. J Immunother. 2010; 34(1):85-91. DOI: 10.1097/CJI.0b013e3181f3cc5c. View

15.

Luco R, Pan Q, Tominaga K, Blencowe B, Pereira-Smith O, Misteli T . Regulation of alternative splicing by histone modifications. Science. 2010; 327(5968):996-1000. PMC: 2913848. DOI: 10.1126/science.1184208. View

16.

Mourah S, Porcher R, Lescaille G, Rousselot P, Podgorniak M, Labarchede G . Quantification of VEGF isoforms and VEGFR transcripts by qRT-PCR and their significance in acute myeloid leukemia. Int J Biol Markers. 2009; 24(1):22-31. DOI: 10.1177/172460080902400104. View

17.

He M, Chen P, Arnovitz S, Li Y, Huang H, Neilly M . Two isoforms of HOXA9 function differently but work synergistically in human MLL-rearranged leukemia. Blood Cells Mol Dis. 2012; 49(2):102-6. PMC: 3399022. DOI: 10.1016/j.bcmd.2012.05.003. View

18.

Davies R, Moore A, Schedl A, BRATT E, Miyahawa K, Ladomery M . Multiple roles for the Wilms' tumor suppressor, WT1. Cancer Res. 1999; 59(7 Suppl):1747s-1750s; discussion 1751s. View

19.

Mizushima Y, Taki T, Shimada A, Yui Y, Hiraumi Y, Matsubara H . Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group. Int J Hematol. 2010; 91(5):831-7. DOI: 10.1007/s12185-010-0585-x. View

20.

Dutertre M, Lacroix-Triki M, Driouch K, De La Grange P, Gratadou L, Beck S . Exon-based clustering of murine breast tumor transcriptomes reveals alternative exons whose expression is associated with metastasis. Cancer Res. 2010; 70(3):896-905. DOI: 10.1158/0008-5472.CAN-09-2703. View